sats 2015 programme

South African Transplantation

Society 26th

BIEN

NIAL CONGR E SS & EXHIB

ITIO

N -

201

5

The Forum @ DiscoverySandton - South Africa

26th South African Transplantation SocietyBiennial Congress and Exhibition

9 - 11 October 2015

Final Programme

Astellas Pharma (Pty) Ltd, Reg. No.: 2002/024956/07, EOH Business Park, 5 Osborne Lane, Bedfordview. Tel: (011) 615 9433. ADV.cycle.ad. 17/04/2015. CI

NGUL

ATE

1026

3

Over time, even subtle changes can add up to real progress. Compared with tacrolimus BID, Advagraf reduces immunosuppression variability1

and non-adherence,*2 and has shown a significant 8% improvement in liver graft survival at 3 years.*3 In transplantation, that’s definitely progress.

Is progress always radical?

* in a large European registry study

S4 ADVAGRAF® 0,5 mg prolonged-release capsules (0,5 mg tacrolimus).

S4 ADVAGRAF® 1 mg prolonged-release capsules (1 mg tacrolimus).

S4 ADVAGRAF® 5 mg prolonged-release capsules (5 mg tacrolimus).

Indications: Prophylaxis of transplant rejection in adult kidney or liver allograft recipients. Treatment of allograft rejection resistant to treatment with other immunosuppressive medicines in adult patients.

Contra-indications: Known hypersensitivity to tacrolimus, the active ingredient in ADVAGRAF®, or other macrolides. Hypersensitivity to any of the excipients of the capsules.

Warnings: Prolonged-release formulations of tacrolimus such as ADVAGRAF® are not interchangeable with immediate-release formulations of tacrolimus, without careful monitoring and supervision by a transplant specialist.

Interactions: ADVAGRAF® is extensively metabolised via the hepatic microsomal cytochrome P-450 system. In particular, ADVAGRAF® showed a broad and powerful inhibitory effect on cytochrome P-450-3A4. ADVAGRAF® is extensively bound to plasma proteins. For this reason, possible interactions with other medicines known to have high affinity for plasma proteins should be considered. During treatment with ADVAGRAF®, vaccinations may be less effective and the use of live attenuated vaccines should be avoided. Care should be taken when using ADVAGRAF® with compounds known to have nephrotoxic effects. When ADVAGRAF® is used together with potentially neurotoxic substances the neurotoxicity of these medicines may be enhanced. As ADVAGRAF® therapy may be associated with hyperkalaemia or may increase pre-existing hyperkalaemia, high potassium intake or potassium-saving diuretics should be avoided.

Pregnancy and lactation: ADVAGRAF® is contra-indicated in pregnancy. Women should not breastfeed whilst receiving ADVAGRAF®. As ADVAGRAF®

may alter the metabolism of oral contraceptives, other forms of contraception should be used.

Dosage and directions for use: ADVAGRAF® dose may vary depending upon the immunosuppressive regimen chosen. Dosing should primarily be based on clinical assessments of rejection and tolerability in each patient individually aided by blood level monitoring. It is recommended that the oral daily dose of ADVAGRAF® be administered once daily in the morning, swallowed with fluid (preferably water). It should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption.

Side-effects: Ischaemic coronary artery disorders, tachycardia. Anaemia, leukopenia, thrombocytopenia, leukocytosis, abnormal red blood cell analyses. Tremor, headache. Seizures, disturbances in consciousness, paraesthesias and dysaesthesias, peripheral neuropathies, dizziness, impaired writing, nervous system disorders. Blurred vision, photophobia, eye disorders. Tinnitus. Dyspnoea, parenchymal lung disorders, pleural effusion, pharyngitis, cough, nasal congestion and inflammation. Diarrhoea, nausea. Gastrointestinal inflammatory conditions, gastrointestinal ulceration and perforation, gastrointestinal haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and symptoms. Renal impairment. Renal failure, acute renal failure, oliguria, renal tubular necrosis, toxic nephropathy, urinary abnormalities, bladder and urethral symptoms. Pruritus, rash, alopecia, acne, increased sweating. Arthralgia, muscle cramps, pain in limb, back pain. Hyperglycaemic conditions, diabetes mellitus, hyperkalaemia. Hypomagnesaemia, hypophosphataemia, hypokalaemia, hypocalcaemia, hyponatraemia, fluid overload, hyperuricaemia, decreased appetite, anorexia, metabolic acidoses, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia,

other electrolyte abnormalities. Increased risk for infections (viral, bacterial, mycobacterial, fungal, protozoal). Primary graft dysfunction. Hypertension. Haemorrhage, thrombembolic and ischaemic events, peripheral vascular disorders, vascular hypotensive disorders. Asthenic conditions, febrile disorders, oedema, pain and discomfort, increased blood alkaline phosphatase, increased weight, disturbed body temperature perception. Allergic and anaphylactoid reactions. Hepatic enzymes and function abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis. Insomnia. Anxiety symptoms, confusion and disorientation, depression, depressed mood, mood disorders and disturbances, nightmare, hallucination, mental disorders.

Registration numbers: ADVAGRAF® 0,5 mg: 42/34/0786; ADVAGRAF® 1 mg: 42/34/0787; ADVAGRAF® 5 mg: 42/34/0788.

Holder of the certificate of registration: Astellas Pharma (Pty) Ltd, Gillooly’s View, 5 Osborne Lane, Bedfordview.

For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority.

References: 1. San’ko-Resmer, J. Boillot O, Wolf P et. al. Renal function, efficacy and safety post conversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transplant Int 2012;25(3);283-293. 2. Beckebaum S, Speranta Iacob S, Sweid D et. al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transplant Int 2011;24(7):666-675. 3. Adam R, Karam V, Delvartet V et. al. Improved Survival in Liver Transplant Recipients Receiving Prolonged-Release Tacrolimus in the European Liver Transplant Registry. Am J Transplant 2015(20):1-16. 4. Astellas Pharma (Pty) Ltd. Advagraf Package Insert, 7 December 2012.

10263 BICYCLE ADVERT .indd 2-3 2015/05/11 9:06 AM

Southern African Transplantation Society

SATS is an organization that confers unity to the entire Transplantation Community of South Africa, maintaining the status quo between a diversity of disciplines and transplant centres, creating a forum for discussion and debate. We provide a neutral platform to engage, determine, and implement policy, particularly with respect to controversial issues, as well as providing a link between a variety of institutions and central government, allowing us to communicate with a single voice.

Additionally, we act as a driving force for research, and facilitate continuing medical education and peer review on a regular basis. SATS remains an organization that continues to evolve, forging the platform for transplantation in the years to come.

Executive Committee

Dr Elmi Muller PresidentDr Jerome Loveland SecretaryProf Russell Britz Past President

Local Organising Committee

Jerome Loveland ChairmanJean Botha Scientific ProgrammeAnna SparacoPaul WilliamsErrol GottlichRussel BritzTrevor GerntholtzMartin SussmanMande Toubkin

Information & Organisation

4

Contents

Information & Organisation 4

Contents 5

Programme at a Glance 7

Scientific Programme 8

Congress Information 11

General Information 12

Exhibition Key 14

Exhibition Floor Plan 15

Notes 17

Sponsors Page 19

5

Netcare Transplant – giving the gift of life and making a difference to the health of our communities.Netcare VCD 7764 | 09.2015

7764 SATS- Biennial Congress Adv Transplant Zon.indd 1 2015/09/23 10:21:25 AM

Programme at a GlanceThursday

8 OCTOBEr 2015Friday

9 OCTOBEr 2015saTurday

10 OCTOBEr 2015sunday

11 OCTOBEr 2015

07:30Registration Registration Registration

08:00

08:15 Welcome and Opening Remarks Opening Remarks Opening Remarks

08:30Plenary Session Plenary Session

Plenary Session

Sponsored by Lagitre International

South Africa Pty Ltd09:15

10:00 Tea / Coffee Break

10:30

Plenary Session and Free Communications

Plenary Session and Free Communications

Debate Session11:00

11:30

12:00 Worst Case Ever! / Never Again12:30

13:00 Lunch Break

14:00

Exhibition Build-Up

14:00 – 20:00

Liver Case Presentation with Expert Panel Plenary Session

14:30

15:00 Tea / Coffee Break

15:30 Kidney / Pancreas Case Presentations with

Expert Panel

Audience Voting

Soap Box Session

Audience Voting16:00

16:30South African Transplant

Society Annual General Meeting

17:00 South African Transplant Society Executive Committee

Meeting

Cocktail reception

Sponsored by Astellas Pharma

17:30

18:00 At Leisure

19:00 Congress Dinner Sponsored by Netcare Foundation At Leisure

7

Scientific ProgrammeFriDAy, 9 OCTOBEr 2015

07:30 – 08:15 registration Foyer

PLENAry SESSiONThe Forum room 2

Chairperson: Jerome Loveland

08:15 – 08:30 Welcome and Opening Remarks Elmi Muller

08:30 – 09:15 Intestinal Rehabilitation and Transplantation: Working Together to Change the Lives of Children and Adults with Intestinal Failure David Mercer

09:15 – 10:00 HIV Transplantation: Current Results and The Way Forward Elmi Muller

10:00 – 10:30 Tea / Coffee Break Exhibition Area

PLENAry SESSiON AND FrEE COMMUNiCATiONSThe Forum room 2

Chairperson: Jerome Loveland and Jean Botha

10:30 – 10:45 Histological Patterns Associated with Late Period Renal Allograft Dysfunction and Loss Sara Saffer

10:45 – 11:00Retrospective Review of Bile Duct Complications Post Liver Transplant in Paediatric Patients Between the Age of 0-16 Years at Wits Donald Gordan Medical Centre over a ten year period

Priya Walabh

11:00 – 11:15 Medical Students' Knowledge about Brain Death: A South African Contribution Sanju Sobnach

11:15 – 11:30 Protecting Liver Grafts from Vascular Complications in Paediatric Liver Transplantation: The Need for Global Peri-operative Approach Jean de Ville de Goyet

11:30 – 11:45 Utility of Serum Creatinine and Proteinuria in the Evaluation of Late Period Graft Dysfunction Sara Saffer

11:45 – 12:00 Infection in Paediatric Transplantation Mignon McCulloch

12:00 – 12:15 Combined Living and Cadaveric Donor Programs: A Successful Strategy for Transplanting Children in an Era of Declining Allocation of PMD Split Liver Grafts Jean de Ville de Goyet

12:15 – 12:30 Population Profile of Adult Patients Presenting for Orthotopic Liver Transplant (OLTx) at the Wits Donald Gordon Medical Centre (WDGMC) Bilal Bobat

12:30 – 13:00 mTORi: Mechanism of Action & Appropriate Clinical Use in Renal Transplantation Josep Campistol

13:00 – 14:00 Lunch Break 2nd Floor

LiVEr CASE PrESENTATiONSThe Forum room 2


14:00 – 15:00 Liver Case Presentation with Expert Panel Experts: David Mercer, Russel Britz, Jean de Ville de Goyet


KiDNEy / PANCrEAS CASE PrESENTATiONSThe Forum room 2

Chairperson: Marcus Schamm

15:30 – 16:30 Kidney / Pancreas Case Presentations with Expert Panel Experts: Vakhtang Rhekviashvilli, Elmi Muller, Trevor Gerntholz

17:00 – 18:00 South African Transplant Society EXCO Meeting Speaker Preparation Room

19:00 Congress Dinner Sponsored by Netcare Foundation Adler Museum of Medicine

8

Scientific ProgrammeSATUrDAy, 10 OCTOBEr 2015



Chairperson: Paul Williams

08:15 – 08:30 Opening Remarks Paul Williams

08:30 – 09:15 Heart Transplantation vs. Mechanical Circulatory Support: Is the Gold Standard Changing Hermann Reichenspurner

09:15 – 10:00 Ex-vivo Perfusion of Donor Organs and Reconditioning Centres Paul Corris


PLENAry SESSiON AND FrEE COMMUNiCATiONSThe Forum room 2

Chairperson: Elmi Muller and russel Britz

10:30 – 11:00 The Current Status of Lung Transplantation Hermann Reichenspurner

11:00 – 11:15 Bridging-to-Transplantation by Mechanical Cardiac Support: Current Status in South Africa Willie Koen

11:15 – 11:30 Lung Transplantation in Johannesburg Marlize Frauendorf

11:30 – 11:45 Videoscopic Assistance in Mechanical Heart Implantation: A Strategy to Minimize Complications Willie Koen

11:45 – 12:00 Cardiothoracic Organ Donation Marlize Frauendorf

12:00 – 12:15 Organ Donation and Transplantation: What do Nurses in Jozi Think? Kim Crymble

12:15 – 12:30 A 10 Year Retrospective Review of Pre-transplant Tissue Compatibility Testing for Cadaveric transplants at the South African National Blood Service Kuben Vather

12:30 – 12:45 Renal Allograft Protocol Biopsy: Findings and Clinical Outcomes in Patients at the Charlotte Maxeke Johannesburg Academic Hospital Fatima Khan

12:45 – 13:00 An Analysis of Reasons why Paediatric Dialysis Patients are Listed for Deceased Donor Transplant at a Tertiary Centre, Johannesburg, South Africa Tholang Khumalo

13:00 – 14:00 Lunch Break Exhibition Area


Chairperson: Jean Botha

14:00 – 14:30 Treating Chronic Lung Allograft Dysfunction (CLAD) and Bossing BOS Paul Corris

14:30 – 15:00 Cancer after Renal Transplantation Josep Campistol


SOAP BOX SESSiONThe Forum room 2


15:30 – 16:30 Soap Box Session and Audience VotingRussel Britz, Errol Gottlich, Elmi Muller, David Mercer, Michael Morford, David Thompson

16:30 – 17:30 South African Transplant Society Annual General Meeting The Forum

17:00 Cocktail reception Sponsored by Astellas Pharma Exhibition Area

9

Scientific ProgrammeSUNDAy, 11 OCTOBEr 2015


PLENAry SESSiONSponsored by Lagitre international South Africa Pty Ltd

The Forum room 2Chairperson: Jerome Loveland

08:15 – 08:30 Opening Remarks Jerome Loveland

08:30 – 09:15 Transplantation and the Microbiome: An Invisible Frontier David Mercer

09:15 – 10:00 Anti-HLA Antibodies in Transplantation: Where are we Now? David Lowe


DEBATEThe Forum room 2

Moderator: Anna Sparaco

10:30 – 11:15 Money in Organ Donation – Donors Should be Compensated Jared Falke vs. Graham Paget

11:15 – 12:00 A Diabetic in Renal Failure with a Live Donor: Wait for SPK or Kidney Transplant Now Followed by PAK

Vakhtang Rhekviashvilli vs. Markus Schamm

12:00 – 13:00 Worst Case Ever! / Never AgainDavid Mercer, Jean Botha, Anthony Beeton, Martin Sussman

12:00 – 13:00 Lunch Break Exhibition Area

10

registration information

The Congress Registration Desk at The Forum @ Discovery will be operational during the following hours:9 October 2015 07h30 – 18h0010 October 2015 07h30 – 18h0011 October 2015 07h30 – 14h00

Speaker Preparation

9 October 2015 07h30 – 17h0010 October 2015 07h30 – 18h0011 October 2015 07h30 – 14h00

Social Events

Congress DinnerFriday, 9th October 2015

Venue: Adler Museum of Medicine Time: 19h00 for 19h30Dress Code: Smart Casual

Cocktail receptionSaturday, 10th October 2015

Time: 17h00 – 19h00Venue: The Atrium @ DiscoveryDress Code: Casual

11

Congress Information

12

General Informationindemnity / insurance

The Congress Organisers have taken reasonable care in making arrangements for the Congress, Exhibition and Social Programme. Neither the Organising Body (SATS), the Local Core Organising Committee, nor its sponsors or committee members assume any responsibility, contractual or delictual for any loss, injury or damage to persons or belongings, or additional expenses incurred as a result of delays or changes in air, rail, sea, road or other services, strikes, sicknesses, weather, or for any acts or omissions by any persons, or for any unforeseen changes to the programme including cancellation of the Congress due to force majeure or any related events or activities. All participants are accordingly advised to make their own arrangements for adequate insurance cover including personal health and travel insurance.

Venue

The Forum @ Discovery16 Fredman DriveSandton

Parking

Limited parking is available at 16 Fredman Drive, Sandton.

Accommodation, Airport Transfers And Tours

If you have not already booked your accommodation, please visit the registration desk for assistance. A facility will be available at the registration desk for participants to book transfers from their hotels to the airport for their departures. The cost of a one way transfer is R380.00 per person. If you require assistance with a tour booking, please visit the registration desk.

Safety

Johannesburg is like any other major city and has good and bad areas. Common sense will ensure a trouble free and enjoyable Congress. During the Congress, the registration desk staff and your hotel concierge will be able to assist you with information on places to visit and the appropriate means of transport.

important Telephone Numbers

Congress Organisers 083 269 0279Netcare 082 911EMRS 10177Police & Flying Squad 10111

Hb control is a result of many factors.You can infl uence one - The choice of ESA.1

Roche provides you with an ESA choice for the majority of your Chronic Kidney

Disease Anaemia patients

When quick correction and

effective control with fl exible dosing is

required 2,3,4

When controlled correction and predictable

maintenance over extended dosing intervals

is required 5,6,7

References: 1. Barany P, Muller H-J. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant 2007;22(Suppl 4):iv 10-iv 18. doi 10.1093/ndt/gfm161. 2. Locatelli F, Pozzoni P, Del Vecchio L. Recombinant human epoetin beta in the treatment of renal anemia. Ther Clin Risk Manag 2007;3(3):433-439. 3. Weiss LG, Clyne N, Fihlho JD, et al. The effi cacy of once weekly compared to two or three times weekly subcutaneous epoetin B: results from a randomised controlled multicentre trial. Nephrol Dial Transplant 2000;15:2014-2019. 4. Tilkian EE, Tzekov VD, et al. Epoetin-beta (Recormon-Roche) in the treatment of renal anemia in patients with chronic renal failure. Folia Med (Plovdiv) 2000;42(3):11-5. 5. Sulowicz W, Locatelli F, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with Chronic Kidney Disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007;2:637-646. 6. Klinger M, Arias M, et al. Effi cacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: A randomized trial. Am J Kid Dis 2007;50(6):989-1000. 7. Saueressig U, Kwan JTC, et al. Healthcare resource utilization for anemia management: Current practice with erythropoiesis stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif 2008;26:537-546.

S4 MIRCERA® 30 µg/0,3 mℓ - 43/8.3/0941; MIRCERA® 50 µg/0,3 mℓ - 42/8.3/0480; MIRCERA® 75 µg/0,3 mℓ - 42/8.3/0481; MIRCERA® 100 µg/0,3 mℓ - 42/8.3/0482; MIRCERA® 120 µg/0,3 mℓ - 43/8.3/0942; MIRCERA® 150 µg/0,3 mℓ - 42/8.3/0483; MIRCERA® 200 µg/0,3 mℓ - 42/8.3/0484; MIRCERA® 250 µg/0,3 mℓ - 42/8.3/0485; MIRCERA® 360 µg/0,6 mℓ - 43/8.3/0943. Each pre� lled syringe contains 30 μg, 50 μg, 75 μg, 100 μg, 120 μg,150 μg, 200 μg, 250 μg or 360 μg methoxy polyethylene glycol-epoetin beta. See package insert. S4 RECORMON® 500 IU/0,3 mℓ: 38/8.3/0499. 2 000 IU/0,3 mℓ: 37/8.3/0567. 4 000 IU/0,3 mℓ: 37/8.3/0568. 6 000 IU/0,3 mℓ: 37/8.3/0569. 10 000 IU/0,6 mℓ: 38/8.3/0500. RECORMON® 30 000 IU/0,6 mℓ: 39/8.3/0105. Contains 500 IU, 2 000 IU, 4 000 IU, 6 000 IU, 10 000 IU or 30 000 IU epoetin beta. Please refer to the package insert for full information. Roche Products (Pty) Ltd. www.roche.co.za 846 Mir16/01

ESA = Erythropoiesis Stimulating Agents

14

Exhibition Key

EXHiBiTOr sTand nO. sTand nO. EXHiBiTOr

Activo Health 8 2 Pharma Dynamics (Pty) Ltd

Astellas Pharma 11 & 12 3 Roche Products (Pty) Ltd

Lagitre International South Africa (Pty) Ltd 6 6 Lagitre International

South Africa (Pty) Ltd

Netcare Foundation 9 7 Novartis South Africa (Pty) Ltd

Novartis South Africa (Pty) Ltd 7 8 Activo Health

Pharma Dynamics (Pty) Ltd 2 9 Netcare Foundation

Roche Products (Pty) Ltd 3 10 Sanofi Transplant

Sanofi Transplant 10 11 & 12 Astellas Pharma

15

Exhibition Floor Plan

MYCOCEPT Advert SATS Cong.indd 1 2015/10/01 12:38 PM

17

Notes

18

Notes

19

Congress Sponsors

Congress Secretariat

For further information conact:

Gill Slaughter Email: [email protected]

SATS Website: www.sats.org.za

http://www.sats.org.za/

sats 2015 programme

Documents